{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:12:37Z","timestamp":1778602357995,"version":"3.51.4"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpm-2025-0250_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the comparative effectiveness of four pharmacologic regimens\u00a0\u2013\u00a0oxytocin, carbetocin, oxytocin plus tranexamic acid (TXA), and carbetocin plus TXA\u00a0\u2013\u00a0for postpartum hemorrhage (PPH) prophylaxis in cesarean deliveries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2025-0250_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective cohort study was conducted at a tertiary center in Istanbul, Turkey, between March 2024 and January 2025. A total of 400 women undergoing cesarean delivery at 34+0\u201339+6\u00a0weeks of gestation were sequentially assigned to one of four prophylactic intervention groups (n=100 each): oxytocin, oxytocin+TXA, carbetocin, or carbetocin+TXA. Medications were administered post-placental delivery. Third-stage labor management was standardized. Primary outcomes included estimated blood loss (EBL), 24-h hemoglobin change (\u0394Hb), and need for transfusion or intravenous iron. Baseline neonatal characteristics, including birthweight and Apgar scores, were recorded to ensure comparability across groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2025-0250_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline characteristics were similar across groups. Hemoglobin decline differed significantly (p=0.015), being lowest in the carbetocin+TXA group (7.73\u00a0\u00b1\u00a06.68\u202f%) and highest in the oxytocin group (10.70\u00a0\u00b1\u00a07.23\u202f%). Although mean EBL was lowest in the carbetocin+TXA group, the difference was not statistically significant (p=0.172). Transfusion and iron supplementation rates were low and comparable. No adverse neonatal outcomes were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2025-0250_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Carbetocin combined with TXA was associated with the most favorable hematologic profile. These findings support the use of multimodal pharmacologic strategies for PPH prevention in cesarean births and may inform future protocol development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpm-2025-0250","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T06:51:24Z","timestamp":1762411884000},"page":"318-324","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of oxytocin, carbetocin, and tranexamic acid for postpartum hemorrhage prevention in cesarean deliveries: a prospective cohort analysis"],"prefix":"10.1515","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-7636","authenticated-orcid":false,"given":"Beyzanur","family":"Kahyao\u011flu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology , 147015 University of Health Sciences Turkey, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital , Istanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9877-1767","authenticated-orcid":false,"given":"Rezzan Berna","family":"Temo\u00e7in","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , 147015 University of Health Sciences Turkey, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital , Istanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8295-0629","authenticated-orcid":false,"given":"Mehmet","family":"G\u00fc\u00e7l\u00fc","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , 147015 University of Health Sciences Turkey, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital , Istanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9750-1594","authenticated-orcid":false,"given":"Mehmet Mete","family":"K\u0131rlang\u0131\u00e7","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , 147015 University of Health Sciences Turkey, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital , Istanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6238-0446","authenticated-orcid":false,"given":"Elif \u00dcnl\u00fcgedik","family":"Say\u0131n","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , 147015 University of Health Sciences Turkey, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital , Istanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5116-3079","authenticated-orcid":false,"given":"Ahmet","family":"\u00d6zkul","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology , 147015 University of Health Sciences Turkey, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital , Istanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"2026051215204207935_j_jpm-2025-0250_ref_001","unstructured":"World Health Organization. A roadmap to combat postpartum haemorrhage between 2023 and 2030. Geneva: World Health Organization; 2023. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240081802."},{"key":"2026051215204207935_j_jpm-2025-0250_ref_002","doi-asserted-by":"crossref","unstructured":"Committee on Practice Bulletins-Obstetrics. Practice bulletin no. 183: postpartum hemorrhage. Obstet Gynecol 2017;130:e168\u201386. https:\/\/doi.org\/10.1097\/AOG.0000000000002351.","DOI":"10.1097\/AOG.0000000000002351"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_003","doi-asserted-by":"crossref","unstructured":"Escobar, MF, Nassar, AH, Theron, G, Barnea, ER, Nicholson, W, Ramasauskaite, D, et al.. FIGO recommendations on the management of postpartum hemorrhage 2022. Int J Gynaecol Obstet 2022;157:3\u201350. https:\/\/doi.org\/10.1002\/ijgo.14116.","DOI":"10.1002\/ijgo.14116"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_004","doi-asserted-by":"crossref","unstructured":"Widmer, M, Piaggio, G, Nguyen, TMH, Osoti, A, Owa, OO, Misra, S, et al.. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. N\u00a0Engl J Med 2018;379:743\u201352. https:\/\/doi.org\/10.1056\/nejmoa1805489.","DOI":"10.1056\/NEJMoa1805489"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_005","doi-asserted-by":"crossref","unstructured":"Jaffer, D, Singh, PM, Aslam, A, Cahill, AG, Palanisamy, A, Monks, DT. Preventing postpartum hemorrhage after cesarean delivery: a network meta-analysis of available pharmacologic agents. Am J Obstet Gynecol 2022;226:347\u201356. https:\/\/doi.org\/10.1016\/j.ajog.2021.08.060.","DOI":"10.1016\/j.ajog.2021.08.060"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_006","doi-asserted-by":"crossref","unstructured":"McDonagh, F, Carvalho, JCA, Abdulla, S, Cordovani, D, Downey, K, Ye, X, et al.. Carbetocin vs oxytocin at elective caesarean delivery: a double-blind, randomised, controlled, non-inferiority trial of low- and high-dose regimens. Anaesthesia 2022;77:892\u2013900. https:\/\/doi.org\/10.1111\/anae.15714.","DOI":"10.1111\/anae.15714"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_007","doi-asserted-by":"crossref","unstructured":"Vernekar, SS, Goudar, SS, Metgud, M, Pujar, YV, Somannavar, MS, Piaggio, G, et al.. Effect of heat-stable carbetocin vs oxytocin for preventing postpartum haemorrhage on post-delivery haemoglobin: a randomized controlled trial. J\u00a0Matern Fetal Neonatal Med 2022;35:8744\u201351. https:\/\/doi.org\/10.1080\/14767058.2021.2001799.","DOI":"10.1080\/14767058.2021.2001799"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_008","doi-asserted-by":"crossref","unstructured":"Rohwer, C, Rohwer, A, Cluver, C, Ker, K, Hofmeyr, GJ. Tranexamic acid for preventing postpartum haemorrhage after caesarean section. Cochrane Database Syst Rev 2024;11:CD016278. https:\/\/doi.org\/10.1002\/14651858.CD016278.pub2.","DOI":"10.1002\/14651858.CD016278"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_009","doi-asserted-by":"crossref","unstructured":"WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with postpartum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017;389:2105\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(17)30638-4.","DOI":"10.1016\/S0140-6736(17)30638-4"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_010","doi-asserted-by":"crossref","unstructured":"Kawakita, T, Mokhtari, N, Huang, JC, Landy, HJ. Evaluation of risk-assessment tools for severe postpartum hemorrhage in women undergoing cesarean delivery. Obstet Gynecol 2019;134:1308\u201316. https:\/\/doi.org\/10.1097\/AOG.0000000000003536.","DOI":"10.1097\/AOG.0000000000003574"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_011","doi-asserted-by":"crossref","unstructured":"Gallos, ID, Papadopoulou, A, Man, R, Athanasopoulos, N, Tobias, A, Price, MJ, et al.. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev 2018;12:CD011689. https:\/\/doi.org\/10.1002\/14651858.CD011689.pub3.","DOI":"10.1002\/14651858.CD011689.pub3"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_012","doi-asserted-by":"crossref","unstructured":"Sentilhes, L, S\u00e9nat, MV, Le Lous, M, Winer, N, Rozenberg, P, Kayem, G, et al.. Tranexamic acid for the prevention of blood loss after cesarean delivery. N\u00a0Engl J Med 2021;384:1623\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2102186.","DOI":"10.1056\/NEJMoa2028788"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_013","doi-asserted-by":"crossref","unstructured":"Simonazzi, G, Bisulli, M, Saccone, G, Moro, E, Marshall, A, Berghella, V. Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials. Acta Obstet Gynecol Scand 2016;95:28\u201335. https:\/\/doi.org\/10.1111\/aogs.12801.","DOI":"10.1111\/aogs.12798"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_014","doi-asserted-by":"crossref","unstructured":"Lee, SH, Kwek, ME, Tagore, S, Wright, A, Ku, CW, Teong, ACA, et al.. Tranexamic acid, as an adjunct to oxytocin prophylaxis, in the prevention of postpartum haemorrhage in women undergoing elective caesarean section: a single-centre double-blind randomised controlled trial. BJOG 2023;130:1007\u201315. https:\/\/doi.org\/10.1111\/1471-0528.17491.","DOI":"10.1111\/1471-0528.17445"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_015","doi-asserted-by":"crossref","unstructured":"von, EE, Altman, DG, Egger, M, Pocock, SJ, Gotzsche, PC, Vandenbroucke, JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e296. https:\/\/doi.org\/10.1371\/journal.pmed.0040296.","DOI":"10.1371\/journal.pmed.0040296"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_016","doi-asserted-by":"crossref","unstructured":"Oladapo, OT, Okusanya, BO, Abalos, E. Intravenous versus intramuscular prophylactic oxytocin for the third stage of labour. Cochrane Database Syst Rev 2020;11:CD009332. https:\/\/doi.org\/10.1002\/14651858.CD009332.pub3.","DOI":"10.1002\/14651858.CD009332.pub4"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_017","doi-asserted-by":"crossref","unstructured":"Heesen, M, Carvalho, B, Carvalho, JCA, Duvekot, JJ, Dyer, RA, Lucas, DN, et al.. International consensus statement on the use of uterotonic agents during caesarean section. Anaesthesia 2019;74:1305\u201319. https:\/\/doi.org\/10.1111\/anae.14779.","DOI":"10.1111\/anae.14757"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_018","doi-asserted-by":"crossref","unstructured":"Stafford, I, Dildy, GA, Clark, SL, Belfort, MA. Visually estimated and calculated blood loss in vaginal and cesarean delivery. Am J Obstet Gynecol 2008;199:519.e1\u20137. https:\/\/doi.org\/10.1016\/j.ajog.2008.04.049.","DOI":"10.1016\/j.ajog.2008.04.049"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_019","doi-asserted-by":"crossref","unstructured":"Maged, AM, Hassan, AM, Shehata, NA. Carbetocin versus oxytocin for prevention of postpartum hemorrhage after vaginal delivery in high risk women. J\u00a0Matern Fetal Neonatal Med 2016;29:532\u20136. https:\/\/doi.org\/10.3109\/14767058.2015.1011121.","DOI":"10.3109\/14767058.2015.1011121"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_020","doi-asserted-by":"crossref","unstructured":"Sentilhes, L, Winer, N, Azria, E, S\u00e9nat, MV, Le Ray, C, Vardon, D, et al.. Tranexamic acid for the prevention of blood loss after vaginal delivery. N\u00a0Engl J Med 2018;379:731\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1800942.","DOI":"10.1056\/NEJMoa1800942"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_021","doi-asserted-by":"crossref","unstructured":"Jones, AJ, Federspiel, JJ, Eke, AC. Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone. Am J Obstet Gynecol MFM 2023;5:100731. https:\/\/doi.org\/10.1016\/j.ajogmf.2022.100731.","DOI":"10.1016\/j.ajogmf.2022.100731"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_022","doi-asserted-by":"crossref","unstructured":"Cheema, HA, Ahmad, AB, Ehsan, M, Shahid, A, Ayyan, M, Azeem, S, et al.. Tranexamic acid for the prevention of blood loss after cesarean section: an updated systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol MFM 2023;5:101049. https:\/\/doi.org\/10.1016\/j.ajogmf.2023.101049.","DOI":"10.1016\/j.ajogmf.2023.101049"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_023","doi-asserted-by":"crossref","unstructured":"Provinciatto, H, Barbalho, ME, da C\u00e2mara, PM, Donadon, IB, Fonseca, LM, Bertani, MS, et al.. Prophylactic tranexamic acid in cesarean delivery: an updated meta-analysis with a trial sequential analysis. Can J Anaesth 2024;71:465\u201372. https:\/\/doi.org\/10.1007\/s12630-024-02715-3.","DOI":"10.1007\/s12630-024-02715-3"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_024","doi-asserted-by":"crossref","unstructured":"El-Goly, NA, Maged, AM, Kamal, WM, Hosny, O, Turki, D, Helmy, NM. Carbetocin versus oxytocin in prevention of postpartum hemorrhage after cesarean delivery in high-risk women: a systematic review and meta-analysis. Arch Gynecol Obstet 2025;312:291\u2013309. https:\/\/doi.org\/10.1007\/s00404-025-08014-6.","DOI":"10.1007\/s00404-025-08014-6"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_025","doi-asserted-by":"crossref","unstructured":"Dawoud, M, Al-Husseiny, M, Helal, O, Elsherbini, M, Abdel-Rasheed, M, Sediek, M. Intravenous tranexamic acid vs sublingual misoprostol in high-risk women for postpartum haemorrhage following cesarean delivery: a randomised clinical trial. BMC Pregnancy Childbirth 2023;23:611. https:\/\/doi.org\/10.1186\/s12884-023-05935-5.","DOI":"10.1186\/s12884-023-05935-5"},{"key":"2026051215204207935_j_jpm-2025-0250_ref_026","unstructured":"World Health Organization. WHO recommendations: uterotonics for the prevention of postpartum haemorrhage. Geneva: World Health Organization; 2018. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535987\/."},{"key":"2026051215204207935_j_jpm-2025-0250_ref_027","unstructured":"Royal College of Obstetricians and Gynaecologists. *Prevention and management of postpartum haemorrhage (Green-top guideline no. 52)*. London: RCOG; 2016. Available from: https:\/\/www.rcog.org.uk\/guidance\/browse-all-guidance\/green-top-guidelines\/prevention-and-management-of-postpartum-haemorrhage-green-top-guideline-no-52\/."},{"key":"2026051215204207935_j_jpm-2025-0250_ref_028","doi-asserted-by":"crossref","unstructured":"Ahmadzia, HK, Luban, NLC, Li, S, Guo, D, Miszta, A, Gobburu, JVS, et al.. Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. Am J Obstet Gynecol 2021;225:85.e1\u201385.e11. https:\/\/doi.org\/10.1016\/j.ajog.2020.11.035.","DOI":"10.1016\/j.ajog.2020.11.035"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpm-2025-0250\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpm-2025-0250\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:28:46Z","timestamp":1778599726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpm-2025-0250\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,19]]},"published-print":{"date-parts":[[2026,2,24]]}},"alternative-id":["10.1515\/jpm-2025-0250"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2025-0250","relation":{},"ISSN":["0300-5577","1619-3997"],"issn-type":[{"value":"0300-5577","type":"print"},{"value":"1619-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}